Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 340

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1
Chunk 340
---
 notes and other information included elsewhere in this Annual
Report.

In
addition to historical financial information, this discussion contains forward-looking statements based upon our current expectations
that involve risks and uncertainties. Our actual results could differ materially from such forward-looking statements as a result of
various factors, including those set forth under “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements”
included elsewhere in this Annual Report. Additionally, our historical results are not necessarily indicative of the results that may
be expected for any period in the future.

Overview

We
are a pre-clinical-stage pharmaceutical company seeking to lead development in age-reversal science. The Company is focused on the development
of Telomir-1, a novel small molecule metal ion regulator, designed to lengthen the DNA’s protective telomere caps, which are
crucial in the aging process. The Company’s goal is to explore the potential of Telomir-1 starting with ongoing research in animals
and then in humans.

We
had net losses of $16.5 million and $13.1 million for the years ended December 31, 2024 and 2023, respectively.

Reverse
Stock Split

Effective
December 11, 2023, we completed a reverse stock split of our outstanding common stock upon the filing of our Second Amended and Restated
Articles of Incorporation with the Florida Secretary of State. No fractional shares were or will be issued in connection with the reverse
stock split, and all such fractional shares resulting from the reverse stock split were and will be rounded up to the nearest whole number.
The shares issuable upon the exercise of our outstanding warrants, and the exercise prices of such warrants, have been adjusted to reflect
the reverse stock split. Unless otherwise noted, the share and per share information in this Annual Report reflects the reverse stock
split.

Components
of our Results of Operations

Research
and Development Expenses

Research
and development expenses represent costs incurred to conduct research and development of our product candidate. We recognize all research
and development costs as they are incurred. Research and development expenses consist primarily of the following:

    ●
    contracted
    research and manufacturing;

    ●
    consulting
    arrangements; and

    ●
    other
    expenses incurred to advance the Company’s research and development activities.

Our
operating expenses have historically been the cost associated with our initial investment in pre-clinical research and development activities.
We expect research and